Related references
Note: Only part of the references are listed.Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Proteome analysis identifies L1CAM/CD171 and DPP4/CD26 as novel markers of human skin mast cells
M. Gschwandtner et al.
ALLERGY (2017)
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Andrew A. Wylie et al.
NATURE (2017)
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
Rebecca Warfvinge et al.
BLOOD (2017)
Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML
Irina Sadovnik et al.
CLINICAL CANCER RESEARCH (2016)
Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells
Haruka Shinohara et al.
CANCER LETTERS (2016)
Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport
Juliana Velez et al.
ONCOTARGET (2016)
Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia
Haruka Shinohara et al.
CANCER LETTERS (2015)
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
Stephane Prost et al.
NATURE (2015)
Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells
Kazuhito Naka et al.
NATURE COMMUNICATIONS (2015)
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
Harald Herrmann et al.
BLOOD (2014)
The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells
Chiharu I. Kobayashi et al.
BLOOD (2014)
S6K1 determines the metabolic requirements for BCR-ABL survival
J. F. Barger et al.
ONCOGENE (2013)
Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy
P. J. Shami et al.
LEUKEMIA (2012)
Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors
Y. Minami et al.
LEUKEMIA (2012)
A PML-PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance
Keisuke Ito et al.
NATURE MEDICINE (2012)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
Su Chu et al.
BLOOD (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
HEMATOLOGY Curing CML with imatinib-a dream come true?
Michael Deininger
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
In Search of CML Stem Cells' Deadly Weakness
Francesca Pellicano et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2011)
Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate
Xiaoyan Jiang et al.
BLOOD (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Insights into the stem cells of chronic myeloid leukemia
I. Sloma et al.
LEUKEMIA (2010)
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia
Y. Chen et al.
LEUKEMIA (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein
Marcus Jaras et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism
Cynthia V. Clower et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Hematopoietic stem cell: self-renewal versus differentiation
Jun Seita et al.
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE (2010)
Translation of the Philadelphia chromosome into therapy for CML
Brian J. Druker
BLOOD (2008)
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy
Akihiro Abe et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Pyruvate kinase M2 is a phosphotyrosine-binding protein
Heather R. Christofk et al.
NATURE (2008)
IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells
Shafaqat Ali et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Junia V. Melo et al.
NATURE REVIEWS CANCER (2007)
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
X. Jiang et al.
LEUKEMIA (2007)
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications
Ingo Roeder et al.
NATURE MEDICINE (2006)
Allosteric inhibitors of Bcr-abl-dependent cell proliferation
FJ Adrián et al.
NATURE CHEMICAL BIOLOGY (2006)
Dynamics of chronic myeloid leukaemia
F Michor et al.
NATURE (2005)
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
CHM Jamieson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
CD25 indicates the neoplastic phenotype of mast cells - A novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens
K Sotlar et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Share Paper
